Literature DB >> 21450266

Copper(II) complexes with tridentate pyrazole-based ligands: synthesis, characterization, DNA cleavage activity and cytotoxicity.

Sofia Gama1, Filipa Mendes, Fernanda Marques, Isabel C Santos, M Fernanda Carvalho, Isabel Correia, João Costa Pessoa, Isabel Santos, António Paulo.   

Abstract

Tridentate pyrazole-containing ligands of the Schiff base type, SalPz - HL(1), Cl(2)SalPz - HL(2) and I(2)SalPz - HL(3), were used to prepare a series of new Cu(II) complexes (CuSalPz - 1, CuCl(2)SalPz - 2 and CuI(2)SalPz - 3). These new complexes have been studied by different analytical techniques (electrospray ionization mass spectrometry (ESI-MS), elemental analysis, FT-IR and EPR). The spectroscopic properties of 1-3 are consistent with the formation of Cu(II) complexes coordinated by monoanionic and tridentate (N,N,O)-chelators, behaving as monomeric species in aqueous solution, as shown by EPR studies. Crystals of 2 and 3, obtained by slow concentration of methanolic solutions of the compounds, were also analyzed by X-ray diffraction analysis. The X-ray structural study has shown that 2 crystallized as a dinuclear compound, [Cu(2)(μ-Cl)(2)(Cl(2)SalPz)(2)], while the solid state structure determined for 3 is best described by monomeric units of [CuCl(I(2)SalPz)] displaying short Cu···Cl intermolecular contacts. The in vitro evaluation of 1-3 comprised the study of their DNA-cleaving ability using plasmid DNA and the assessment of their cytotoxic activity against several human cancer cell lines (PC-3 prostate, MCF-7 breast and A2780 and A2780cisR-ovary). The studies with plasmid DNA have shown that 2 and 3 induce extensive DNA cleavage in the presence of different additives. The cytotoxic activity of 2 and 3 is comparable to the one presented by cisplatin, with the exception of the A2780 cell line where cisplatin is more active. It has been found that the introduction of halogen substituents in the phenolate rings of the chelators enhanced the cytotoxicity of the respective Cu(II) complexes.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21450266     DOI: 10.1016/j.jinorgbio.2011.01.013

Source DB:  PubMed          Journal:  J Inorg Biochem        ISSN: 0162-0134            Impact factor:   4.155


  6 in total

1.  Hydrogen bonding and anticancer properties of water-soluble chiral p-cymene Ru(II) compounds with amino-oxime ligands.

Authors:  Yosra Benabdelouahab; Laura Muñoz-Moreno; Malgorzata Frik; Isabel de la Cueva-Alique; Mohammed Amin El Amrani; María Contel; Ana M Bajo; Tomás Cuenca; Eva Royo
Journal:  Eur J Inorg Chem       Date:  2015-04-09       Impact factor: 2.524

2.  Co(II), Ni(II), and Zn(II) complexes based on new hybrid imine-pyrazole ligands: structural, spectroscopic, and electronic properties.

Authors:  Gabriel Rodrigues Martins; Cristiane Storck Schwalm; Cláudio Teodoro de Carvalho; Leandro Moreira de Campos Pinto
Journal:  J Mol Model       Date:  2022-05-21       Impact factor: 1.810

3.  Antioxidant and cytotoxic activities of selected salicylidene imines: experimental and computational study.

Authors:  Jovica Branković; Marios G Krokidis; Irini Dousi; Kyriakos Papadopoulos; Zorica D Petrović; Vladimir P Petrović
Journal:  Mol Divers       Date:  2022-02-11       Impact factor: 2.943

4.  A fluorescent Cu(ii) complex as a dual functional sensor for selective and sensitive detection of acetone and Cd(ii) pollutants.

Authors:  Mohd Muddassir; Abdullah Alarifi; Mohd Afzal; Khulud Abdullah Alshali; Naaser A Y Abduh; Abeer Beagan
Journal:  RSC Adv       Date:  2020-11-18       Impact factor: 4.036

5.  Design and Anticancer Properties of New Water-Soluble Ruthenium-Cyclopentadienyl Complexes.

Authors:  Tânia S Morais; Fernanda Marques; Paulo J Amorim Madeira; Maria Paula Robalo; Maria Helena Garcia
Journal:  Pharmaceuticals (Basel)       Date:  2022-07-14

6.  2-Mercaptobenzimidazole clubbed hydrazone for Alzheimer's therapy: In vitro, kinetic, in silico, and in vivo potentials.

Authors:  Farida Begum; Najeeb Ur Rehman; Ajmal Khan; Sajid Iqbal; Rehan Zafar Paracha; Jalal Uddin; Ahmed Al-Harrasi; Muhammad Arif Lodhi
Journal:  Front Pharmacol       Date:  2022-08-09       Impact factor: 5.988

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.